Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class…
Search
Have an existing account? Sign In
Tag: 925